Drug Makers Stocks Under Review -- Pfizer, Merck, AbbVie, and Johnson & Johnson
NEW YORK, September 21, 2016 /PRNewswire/ --
The Drug Manufacturers space is engaged in the development, production and marketing of medications. Its leading companies are based mainly in the United States and Europe. Today, Stock-Callers.com takes a look at the recent performances of four major stocks within this industry: Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). Learn more about these stocks by downloading their free research reports in PDF format at: http://stock-callers.com/registration
Pfizer
On Tuesday, shares in New York headquartered Pfizer Inc. recorded a trading volume of 14.11 million shares. The stock ended the day at $33.81, rising 0.48%. The Company's shares have gained 7.63% on an YTD basis. The stock is trading above its 200-day moving average by 4.01%. Furthermore, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 35.85.
On September 16th, 2016, Pfizer announced that the confirmatory study evaluating the efficacy, safety, and immunogenicity of PF-06438179 (infliximab-Pfizer) compared to Remicade® (infliximab) met its primary endpoint. The trial demonstrated equivalent efficacy of the proposed biosimilar PF-06438179 to the originator product as measured by the American College of Rheumatology 20 (ACR20) response at Week 14. PF-06438179 is being developed as a potential biosimilar to Remicade. Sign up and read the free research report on PFE at: http://stock-callers.com/registration/?symbol=PFE
Merck
Kenilworth, New Jersey headquartered Merck & Co. Inc.'s stock finished yesterday's session 0.99% higher at $61.94 and with a total trading volume of 9.20 million shares. The Company's shares have gained 10.92% over the previous three months and 20.13% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.68% and 13.13%, respectively. Furthermore, shares of Merck & Co., which provides health care solutions worldwide, have an RSI of 51.14.
On September 9th, 2016, research firm Barclays reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $66 a share to $72 a share.
On September 12th, 2016, - Merck announced that BRENZYS™ (etanercept) received approval in Canada for the treatment of adult patients with moderate to severe rheumatoid arthritis and ankylosing spondylitis. BRENZYS™ is a biosimilar to the originator biologic Enbrel®* and the first subcutaneous anti-tumor necrosis factor (anti-TNF) biosimilar medicine available in Canada. The complimentary research report on MRK can be downloaded at: http://stock-callers.com/registration/?symbol=MRK
AbbVie
At the closing bell on Tuesday, shares in North Chicago, Illinois-based AbbVie Inc. climbed 0.59%, ending the day at $63.28. The stock recorded a trading volume of 4.83 million shares. The Company's shares have advanced 6.43% in the previous three months and 9.94% since the start of this year. The stock is trading 6.64% above its 200-day moving average. Moreover, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 40.82.
On September 8th, 2016, research firm JP Morgan downgraded the Company's stock rating from 'Overweight' to 'Neutral'.
On September 20th, 2016, Karolinska Development AB announced that its portfolio company BioArctic AB has entered into a strategically important collaboration with AbbVie, to develop and commercialize BioArctic's portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson's disease and other potential indications. Register for free on Stock-Callers.com and access the latest report on ABBV at: http://stock-callers.com/registration/?symbol=ABBV
Johnson & Johnson
New Brunswick, New Jersey-based Johnson & Johnson's stock ended the day 0.25% higher at $117.95 and with a total trading volume of 5.18 million shares. The Company's shares have gained 2.20% over the previous three months and 17.26% on an YTD basis. The stock is trading 6.80% above its 200-day moving average. Additionally, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 38.76.
On September 16th, 2016, Johnson & Johnson announced a definitive agreement to acquire Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott Laboratories, for $4.325 billion in cash. AMO reported sales of $1.1 billion for 2015. The acquisition will include ophthalmic products in three business segments: cataract surgery, laser refractive surgery and consumer eye health. The acquisition also includes AMO's consumer eye health products - over-the-counter drops for dry eye, as well as multipurpose solutions and hydrogen peroxide cleaning systems for patients who wear contact lenses. The transaction is expected to close in Q1 2017 and is subject to antitrust clearance and other customary closing conditions. Get free access to your research report on JNJ at: http://stock-callers.com/registration/?symbol=JNJ
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article